Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction☆
Abstract
Sinus tachycardia often accompanies other indicators of poor prognosis in acute myocardial infarction. This study was performed to evaluate the prognostic significance of early (Days 1 to 3) inhospital sinus tachycardia (isolated sinus tachycardia) in the absence of other common indicators of poor prognosis. All patients consecutively admitted directly to the cardiac care unit during a six-year period were evaluated. Patients who had confirmed acute myocardial infarction and no urgent complications during Days 1 to 3 with isolated sinus tachycardia (99 patients) or without isolated sinus tachycardia (159 patients) were included in the study. Both groups were followed for subsequent in-hospital outcome and long-term survival. Univariable and multivariable analysis of historical and demographic characteristics showed no significant differences between the two groups. When clinical descriptors of the infarct were evaluated, the group with isolated sinus tachycardia had a significantly higher mean peak creatine kinase level (p = 0.0007), a larger proportion of anterior infarcts and multiple infarct sites (p < 0.001) by electrocardiography, a higher incidence of peri-infarction pericarditis (p = 0.007), and a higher incidence of recurrent chest pain (p = 0.03). Twenty-five patients (25 percent) in the group with isolated sinus tachycardia had subsequent urgent complications during the hospitalization compared with 11 patients (7 percent) in the control group (p = 0.00005). In multivariable analysis, isolated sinus tachycardia was an independent predictor of subsequent urgent complications (p = 0.0009) and mortality (p = 0.05).
No full text is available. To read the body of this article, please view the PDF online.
To access this article, please choose from the options below
☆ This work was supported in part by Research Grant HS-03834 from the National Center for Health Services Research and the National Center for Health Care Technology, by Research Grant HL-17670 from the National Heart, Lung, and Blood Institute, and by grants from the Prudential Insurance Company of America, the Kaiser Family Foundation, and the Andrew W. Mellon Foundation.
PII: 0002-9343(84)90846-5
© 1984 Published by Elsevier Inc.

